Targeted disrupting BCL9/β-catenin interaction by an endosomal-escapable nanoparticle functionalized with an E-cadherin-derived peptide.
The abnormal activation of Wnt/β-Catenin signal pathway, underlying multiple malignancies, promotes tumor progression, blocking this pathway highly attractive drug candidates for anticancer therapy. Using a peptide therapeutic derived from E-cadherin region Ⅴ (cECRⅤ), we sought to develop a potent and selective antagonist against β-Catenin via disrupting the carcinogenic interaction between β-Catenin and BCL9. More importantly, to overcome the pharmacological obstacle of peptide-derived therapeutics: poor nucleases stability and low membrane permeability, a gold nanoparticle (AuNP)-based nanocarrier was designed to delivery cECRⅤ into cytoplasm to modulate the intracellular β-Catenin-Bcl9 interaction. The resultant nanoparticle pAuNP-cECRⅤ, while no cytotoxicity towards normal PBMC cells, induced cycle arrest and subsequent apoptosis of Wnt-hyperactive cancer cells by antagonizing β-Catenin to inhibit the Wnt pathway. Our results indicated that pAuNP-cECRⅤ exhibited remarkable potential application as an efficient and safe peptide delivery vector for cancer therapy.